Human amylin proteotoxicity impairs protein biosynthesis, and alters major cellular signaling pathways in the heart, brain and liver of humanized diabetic rat model in vivo

Metabolomics

Volumn 12, Issue 5, 2016, Pages

  Ilaiwy, Amro ^a,d,e   Liu, Miao ^b   Parry, Traci L ^c   Bain, James R ^d,e   Newgard, Christopher B ^d,e   Schisler, Jonathan C ^c   Muehlbauer, Michael J ^d   Despa, Florin ^b   Willis, Monte S ^c  

^a DAMASCUS UNIVERSITY   (Syrian Arab Republic)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Amylin; Cardiomyopathy; Diabetes; Metabolomics; Neurodegenerative disease; Proteotoxicity

Indexed keywords

5 AMINOVALERIC ACID; ALANINE; AMYLIN; PHENYLALANINE; TYROSINE;

AMINO ACID METABOLISM; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; GENOTYPE PHENOTYPE CORRELATION; GLUCONEOGENESIS; GLUCOSE METABOLISM; MALE; MASS SPECTROMETRY; METABOLOMICS; NONHUMAN; PRINCIPAL COMPONENT ANALYSIS; PROTEIN SYNTHESIS; PROTEOTOXICITY; RAT; SIGNAL TRANSDUCTION; TOXICITY; VALIDATION PROCESS;

EID: 84964253599     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-016-1022-9     Document Type: Article

References (36)

1. Ashford, A. J., & Pain, V. M. (1986). Effect of diabetes on the rates of synthesis and degradation of ribosomes in rat muscle and liver in vivo. Journal of Biological Chemistry,261, 4059–4065.
2. Aung, M. H., et al. (2014). Dopamine deficiency contributes to early visual dysfunction in a rodent model of type 1 diabetes. Journal of Neuroscience,34, 726–736. doi:10.1523/JNEUROSCI.3483-13.2014.
3. Banerjee, R., et al. (2015). Non-targeted metabolomics of double-mutant cardiomyocytes reveals a novel role for SWI/SNF complexes in metabolic homeostasis. Metabolomics,11, 1287–1301. doi:10.1007/s11306-015-0786-7.
4. Boirie, Y., Short, K. R., Ahlman, B., Charlton, M., & Nair, K. S. (2001). Tissue-specific regulation of mitochondrial and cytoplasmic protein synthesis rates by insulin. Diabetes,50, 2652–2658.
5. Castellani, R. J., et al. (2001). Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine. Free Radical Biology and Medicine,31, 175–180.
6. Despa, S., et al. (2012). Hyperamylinemia contributes to cardiac dysfunction in obesity and diabetes: A study in humans and rats. Circulation Research,110, 598–608. doi:10.1161/CIRCRESAHA.111.258285.
7. Despa, S., et al. (2014). Cardioprotection by controlling hyperamylinemia in a “humanized” diabetic rat model. Journal of the American Heart Association,3, e001015. doi:10.1161/JAHA.114.001015.
8. Dunn, L., et al. (2014). Dysregulation of glucose metabolism is an early event in sporadic Parkinson’s disease. Neurobiology of Aging,35, 1111–1115. doi:10.1016/j.neurobiolaging.2013.11.001.
9. Erickson, J. R., et al. (2013). Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature,502, 372–376. doi:10.1038/nature12537.
10. Fernstrom, J. D., & Fernstrom, M. H. (2007). Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. The Journal of Nutrition,137(6), 1539S–1547S. discussion 1548S.
11. Gonzalez-Dominguez, R., Garcia-Barrera, T., & Gomez-Ariza, J. L. (2015). Metabolite profiling for the identification of altered metabolic pathways in Alzheimer’s disease. Journal of Pharmaceutical and Biomedical Analysis,107, 75–81. doi:10.1016/j.jpba.2014.10.010.
12. Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015). Amylin: Pharmacology, physiology, and clinical potential. Pharmacological Reviews,67, 564–600. doi:10.1124/pr.115.010629.
13. Jackson, K., Barisone, G. A., Diaz, E., Jin, L. W., DeCarli, C., & Despa, F. (2013). Amylin deposition in the brain: A second amyloid in Alzheimer disease? Annals of Neurology,74, 517–526. doi:10.1002/ana.23956.
14. Jorda, A., Gomez, M., Cabo, J., & Grisolia, S. (1982). Effect of streptozotocin diabetes on some urea cycle enzymes. Biochemical and Biophysical Research Communications,106, 37–43.
15. Kouzu, H., et al. (2015). Excessive degradation of adenine nucleotides by up-regulated AMP deaminase underlies afterload-induced diastolic dysfunction in the type 2 diabetic heart. Journal of Molecular and Cellular Cardiology,80, 136–145. doi:10.1016/j.yjmcc.2015.01.004.
16. +—Glucose cotransport. Journal of the American Heart Association,4, e002183. doi:10.1161/JAHA.115.002183.
17. Lapidot, A., & Haber, S. (2001). Effect of endogenous β-hydroxybutyrate on glucose metabolism in the diabetic rabbit brain: A (13)C-magnetic resonance spectroscopy study of [U-(13)C]glucose metabolites. Journal of Neuroscience Research,64, 207–216.
18. Li, L. O., Hu, Y. F., Wang, L., Mitchell, M., Berger, A., & Coleman, R. A. (2010). Early hepatic insulin resistance in mice: A metabolomics analysis. Molecular Endocrinology,24, 657–666. doi:10.1210/me.2009-0152.
19. Lutz, T. A., & Meyer, U. (2015). Amylin at the interface between metabolic and neurodegenerative disorders. Frontiers in Neuroscience,9, 216. doi:10.3389/fnins.2015.00216.
20. Makinen, K. K. (2000). Can the pentitol-hexitol theory explain the clinical observations made with xylitol? Medical Hypotheses,54, 603–613. doi:10.1054/mehy.1999.0904.
21. Mans, A. M., DeJoseph, M. R., Davis, D. W., & Hawkins, R. A. (1987). Regional amino acid transport into brain during diabetes: Effect of plasma amino acids. American Journal of Physiology,253, E575–E583.
22. Pasini, E., Aquilani, R., Corsetti, G., & Dioguardi, F. S. (2014). Biomarkers to identify protein metabolism impairment in chronic/acute diseases. Journal of Molecular Biomarkers & Diagnosis,5, 176–179.
23. Pasini, E., Aquilani, R., & Dioguardi, F. S. (2013). The enemy within. How to identify chronic diseases induced-protein metabolism impairment and its possible pharmacological treatment. Pharmacological Research,76, 28–33. doi:10.1016/j.phrs.2013.06.006.
24. Pietzsch, J., Bergmann, R., & Kopprasch, S. (2004). Analysis of non-protein amino acids as specific markers of low density lipoprotein apolipoprotein B-100 oxidation in human atherosclerotic lesions: The use of N(O)-ethoxycarbonyl trifluoroethyl ester derivatives and GC-MS. Spectroscopy,18, 177–183.
25. Rampersad, O. R., & Wool, I. G. (1965). Protein synthesis by ribosomes from heart muscle: Effect of insulin and diabetes. Science,149, 1102–1103.
26. Reusch, R. N., Bryant, E. M., & Henry, D. N. (2003). Increased poly-(R)-3-hydroxybutyrate concentrations in streptozotocin (STZ) diabetic rats. Acta Diabetologica,40, 91–94. doi:10.1007/s005920300011.
27. Scholtens, D. M., et al. (2014). Metabolomics reveals broad-scale metabolic perturbations in hyperglycemic mothers during pregnancy. Diabetes Care,37, 158–166. doi:10.2337/dc13-0989.
28. Schutz, Y. (2011). Protein turnover, ureagenesis and gluconeogenesis. International Journal for Vitamin and Nutrition Research,81, 101–107. doi:10.1024/0300-9831/a000064.
29. Srodulski, S., et al. (2014). Neuroinflammation and neurologic deficits in diabetes linked to brain accumulation of amylin. Mol Neurodegener,9, 30. doi:10.1186/1750-1326-9-30.
30. Tillin, T., et al. (2015). Diabetes risk and amino acid profiles: Cross-sectional and prospective analyses of ethnicity, amino acids and diabetes in a South Asian and European cohort from the SABRE (Southall And Brent REvisited) Study. Diabetologia,58, 968–979. doi:10.1007/s00125-015-3517-8.
31. Tiwari, V., & Patel, A. B. (2014). Pyruvate carboxylase and pentose phosphate fluxes are reduced in AbetaPP-PS1 mouse model of Alzheimer’s disease: A (1)(3)C NMR study. Journal of Alzheimer’s Disease,41, 387–399. doi:10.3233/JAD-122449.
32. Verdile, G., Fuller, S. J., & Martins, R. N. (2015). The role of type 2 diabetes in neurodegeneration. Neurobiology of Diseases. doi:10.1016/j.nbd.2015.04.008.
33. Wootton-Gorges, S. L., et al. (2005). Detection of cerebral β-hydroxy butyrate, acetoacetate, and lactate on proton MR spectroscopy in children with diabetic ketoacidosis. American Journal of Neuroradiology,26, 1286–1291.
34. Wurtz, P., et al. (2015). Metabolite profiling and cardiovascular event risk: A prospective study of 3 population-based cohorts. Circulation,131, 774–785. doi:10.1161/CIRCULATIONAHA.114.013116.
35. Xia, J., Psychogios, N., Young, N., & Wishart, D. S. (2009). MetaboAnalyst: A web server for metabolomic data analysis and interpretation. Nucleic Acids Research,37, W652–W660. doi:10.1093/nar/gkp356.
36. Xia, J., Sinelnikov, I. V., Han, B., & Wishart, D. S. (2015). MetaboAnalyst 3.0—Making metabolomics more meaningful. Nucleic Acids Research,43, W251–W257. doi:10.1093/nar/gkv380.